1. A method of treating a person having or presumably having a disease associated with aberrant B-cell activity, comprising administering to a person a therapeutically effective single dose of a CD20-specific binding molecule. ! 2. A method of treating a person having or presumably having a rheumatic disease, comprising administering to a person a therapeutically effective single dose of a CD20 specific binding molecule. ! 3. The method according to claim 2, where the rheumatic disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, dermatomyositis, Shenlein-Genoch disease, juvenile rheumatoid arthritis, psoriatic arthritis, Raynaud's syndrome, Reiter's syndrome, sarcoidosis, spondylitis, spondylitis, spondylitis, spondylitis and myositis. ! 4. The method according to claim 3, where the disease is rheumatoid arthritis. ! 5. The method according to claim 4, where the introduction of a CD20-specific binding molecule results in an ACR score of 20. equal to! 6. The method according to claim 4, where the number of b-cells in a biological sample of a person is reduced. ! 7. The method according to claim 4, where the expression of the RANK ligand in a biological sample of a person is reduced. ! 8. The method according to claim 6 or 7, where the biological sample is a blood, synovial fluid or synovial biopsy. ! 9. A method of treating a person having or presumably having an inflammatory intestinal disease, comprising administering to a person a therapeutically effective single dose of a CD20-specific binding molecule. ! 10. The method according to claim 9, where the inflammatory intestinal disease is selected from the group consisting of ulcerative colitis and Crohn's disease. ! 11. Method1. Способ лечения человека, имеющего или предположительно имеющего заболевание, связанное с аберрантной В-клеточной активностью, включающий введение человеку терапевтически эффективной однократной дозы CD20-специфической связывающей молекулы. ! 2. Сп
